Stock Market Crash Warning: Don’t Get Caught Holding These 3 Cathie Wood Stocks

Stock Market Crash Warning: Don’t Get Caught Holding These 3 Cathie Wood Stocks

 https://youtu.be/mvs3wU5UVX0?si=kUI51wPLISIGBfhs

Investors may want to steer clear of three Cathie Wood stocks that are in deep trouble

 

With Ark Invest’s holdings in a downturn, investors should avoid these three Cathie Wood stocks today.

Teladoc Health (TDOC): Telehealth services are in decline as people have returned to in-person doctor’s appointments.

Moderna (MRNA): The company’s Covid-19 vaccine sales plunged, with no apparent revenue replacement yet.

Archer Aviation (ACHR): Its flying taxis could be interesting, but the company is years away from profitability.

 

아크 인베스트의 보유 주식이 침체된 상황에서 투자자들은 오늘 이 세 개의 캐시 우드 주식을 피해야 합니다.

텔라독 헬스(TDOC): 사람들이 직접 의사 진료 예약으로 돌아감에 따라 원격 의료 서비스가 감소하고 있습니다.

모더나(MRNA): 회사의 코로나19 백신 판매는 급감했고, 뚜렷한 수익 대체는 아직 없습니다.

Archer Aviation (ACHR): 하늘을 나는 택시는 흥미로울 수 있지만, 그 회사는 수익성이 몇 년 남지 않았습니다.

For a time, Cathie Wood was the hottest investor on Wall Street. Ark Invest was bringing in billions of dollars in new assets under management. She launched a diversified suite of exchange-traded funds (ETFs) targeting fields such as technology, 3-D printing, medicine, robotics and space.

 

However, her star has quickly fallen. The flagship fund has now underperformed the relevant comparison, the Nasdaq 100, on virtually all applicable time frames. A February report found that in aggregate, her funds have lost investors billions of dollars. Also, investors are rapidly pulling money out of her ETFs.

 

It seems that Cathie Wood’s moment has passed. So, investors should strongly consider reducing their exposure to her stocks before losing additional value. These are three Cathie Wood stocks to sell today.

한동안, 캐시 우드(Cathie Wood)는 월가에서 가장 인기 있는 투자자였습니다. 아크 인베스트(Ark Invest)는 관리 하에 수십억 달러의 새로운 자산을 끌어들이고 있었습니다. 그녀는 기술, 3-D 프린팅, 의학, 로봇 공학 및 우주와 같은 분야를 대상으로 다양한 상장지수펀드(ETF) 제품군을 출시했습니다.

 

하지만, 그녀의 별은 빠르게 하락했습니다. 대표 펀드는 현재 거의 모든 해당 기간 동안 관련 비교 지수인 나스닥 100을 하회했습니다. 2월 보고서에 따르면, 그녀의 펀드는 총 수십억 달러의 투자자를 잃었습니다. 또한, 투자자들은 그녀의 ETF에서 빠르게 돈을 인출하고 있습니다.

 

캐시 우드의 시점은 지난 것 같습니다. 따라서, 투자자들은 추가적인 가치를 잃기 전에 그녀의 주식에 대한 노출을 줄이는 것을 강력하게 고려해야 합니다. 이것들은 오늘 팔아야 할 세 개의 캐시 우드 주식입니다.

Teladoc Health (TDOC)

Like many of Ark’s picks, Teladoc Health (NYSE:TDOC) was a perfect stock for 2021. With people in isolation as Covid-19 swept the world, they were open to the idea of virtual medicine. Telehealth seemed like a perfect concept, so Teladoc Health shares absolutely skyrocketed.

 

But then, it made an expensive merger with a key rival, Livongo, which almost immediately destroyed major shareholder value. Teladoc Health would report a shocking $13.7 billion loss in 2022. Most of that came as a write-down on the disastrous Livongo deal.

 

And now, it seems the telemedicine movement has crashed and burned. Most people prefer seeing a doctor in person unless there are extenuating circumstances. Just over the past week, both Walmart (NYSE:WMT) and giant health insurer UnitedHealth (NYSE:UNH) have announced that they are shutting down their telehealth divisions due to a lack of consumer demand. When the biggest players in the industry say that the business model isn’t working, that should give investors a clear warning.

 

For the time being, Teladoc Health is still soldiering on. But shares are rapidly losing value, given the company’s massive red ink with no apparent paths to stop the bleeding.

아크의 많은 사람들처럼, 텔라독 헬스(NYSE:TDOC)는 2021년에 완벽한 주식이었습니다. 코로나19가 전 세계를 휩쓸면서 사람들이 고립된 상황에서, 그들은 가상 의학에 대한 생각에 열려 있었습니다. 텔레헬스는 완벽한 개념처럼 보였기 때문에, 텔라독 헬스의 주가는 절대적으로 급등했습니다.

 

하지만 그 후 주요 경쟁사인 리봉고와 고가의 합병을 성사시켰고, 이는 거의 즉시 주요 주주 가치를 무너뜨렸습니다. 텔라독 헬스는 2022년에 충격적인 137억 달러의 손실을 보고할 것입니다. 그 대부분은 재앙에 가까운 Livongo 거래에 대한 기록이었습니다.

 

그리고 지금은 원격의료 움직임이 붕괴되어 불타고 있는 것 같습니다. 대부분의 사람들은 특별한 사정이 없는 한 직접 의사를 만나는 것을 선호합니다. 지난 주에 월마트(NYSE:WMT)와 거대 건강보험사 유나이티드헬스(NYSE:UNH)는 모두 소비자 수요 부족으로 인해 원격의료 사업부를 폐쇄한다고 발표했습니다. 업계의 가장 큰 주체들이 비즈니스 모델이 작동하지 않는다고 말할 때, 이는 투자자들에게 명확한 경고를 줄 것입니다.

 

당분간, 텔라독 헬스는 여전히 매도 중입니다. 그러나 출혈을 막을 뚜렷한 길이 없는 회사의 엄청난 적자를 감안할 때, 주식은 빠르게 가치를 잃고 있습니다.

Moderna (MRNA)

Like with Teladoc, Moderna (NASDAQ:MRNA) was briefly a high-flying growth stock but the bull case has long since disappeared.

 

Moderna was one of the first biotech companies to develop an effective vaccine for the Covid-19 virus. Ultimately, Moderna would go on to earn tens of billions of dollars from this vaccine. Investors would bid MRNA stock up to the stratosphere. They believed the company would continue to thrive following its blockbuster vaccine. But that didn’t materialize.

 

Vaccine sales collapsed as the pandemic has receded, and people show less interest in taking booster shots. At the same time, Moderna has been unable to find any other meaningful new revenue contributors to make up for the collapse of its core COVID-19 vaccine sales.

 

As a result, the company’s revenues have plummeted, slumping from $19.3 billion in 2022 to a mere estimated $4.2 billion this year. Not surprisingly, Moderna has fallen into sharply unprofitable territory, with the company losing $4.7 billion in 2023.

 

Bulls are hoping that the company will develop another winning vaccine sooner or later, but that’s a pretty thin bull case. I expect MRNA stock to eventually settle somewhere around its book value or cash value per share. Those figures are $36 and $23 per share respectively, suggesting the stock has at least two-thirds more downside going forward.

텔라독과 마찬가지로 모더나(NASDAQ:MRNA)는 잠시 고성장주였지만 강세장은 사라진 지 오래입니다.
 
모더나는 코로나19 바이러스에 효과적인 백신을 개발한 최초의 바이오텍 기업 중 하나였습니다. 모더나는 궁극적으로 이 백신으로 수백억 달러의 수익을 올릴 것입니다. 투자자들은 MRNA 주식을 성층권까지 입찰할 것입니다. 그들은 회사가 블록버스터 백신 이후에도 계속해서 번창할 것이라고 믿었습니다. 그러나 그것은 실현되지 않았습니다.
 
팬데믹이 줄어들면서 백신 판매가 줄었고, 사람들은 부스터샷 접종에 대한 관심을 덜 보입니다. 동시에 모더나는 핵심 코로나19 백신 판매의 붕괴를 만회할 다른 의미 있는 새로운 수익 기여자를 찾지 못했습니다.
 
그 결과 회사의 매출은 급감하여 2022년 193억 달러에서 올해 42억 달러로 감소했습니다. 놀랍지 않은 사실은 모더나는 2023년에 47억 달러의 손실을 입으면서 수익성이 급격히 떨어지는 영역에 빠졌습니다.
 
강세론자들은 회사가 조만간 또 다른 성공적인 백신을 개발하기를 바라고 있지만, 이는 상당히 희박한 강세론자 사례입니다. 저는 MRNA 주식이 결국 장부 가치나 주당 현금 가치를 중심으로 정착할 것으로 예상합니다. 이 수치는 각각 주당 36달러와 23달러로, 향후 주가가 적어도 3분의 2 이상 하락할 가능성이 있음을 시사합니다.

Archer Aviation (ACHR)

 

Archer Aviation (NYSE:ACHR) is one of several companies manufacturing an electric vertical take-off and landing vehicle (eVTOL). Some people refer to these as flying cars. The premise behind eVTOL is they are more attractive than private helicopters and will greatly expand the urban air taxi marketplace.

 

A couple of years ago, traders were willing to pay almost any price for unproven business models that promised potentially huge upside if things went well. However, now investors largely shun these sorts of concept stocks. They often have no revenues, large cash burn and unproven commercial business models.

 

It’s quite possible that Archer Aviation will eventually be able to make it to market with a revenue generating service that attracts customer demand. On the other hand, plenty of reason for doubt brews. And, it doesn’t appear Archer Aviation is likely to try to launch commercial services until its planned 2026 debut in India.

 

That’s a long time to wait to see if the business model works as we face high interest rates among geopolitical pressures. Unfortunately, ACHR stock is unlikely to pay off anytime soon, making this another Cathie Wood stock to sell today.

Archer Aviation (NYSE:ACHR)은 전기 수직 이착륙 차량 (eVTOL)을 제조하는 여러 회사 중 하나입니다. 어떤 사람들은 이것들을 하늘을 나는 자동차라고 부릅니다. eVTOL의 전제는 그것들이 개인 헬리콥터보다 더 매력적이고 도시의 에어 택시 시장을 크게 확장 할 것이라는 것입니다.
 
몇 년 전만 해도 거래자들은 일이 잘 풀리면 엄청난 상승을 약속하는 검증되지 않은 비즈니스 모델에 대해 거의 모든 가격을 기꺼이 지불했습니다. 그러나 이제 투자자들은 이러한 종류의 컨셉 주식을 대부분 피합니다. 그들은 종종 수익이 없고 현금이 많이 소모되며 검증되지 않은 상업 비즈니스 모델을 가지고 있습니다.
 
Archer Aviation은 결국 고객의 수요를 끌어들이는 수익 창출 서비스로 시장에 진출할 수 있을 가능성이 높습니다. 반면 의심할 만한 이유는 많습니다. 그리고 Archer Aviation은 2026년 인도에서 계획된 첫 선을 보일 때까지 상업 서비스를 시작하려고 시도하지 않을 것으로 보입니다.
 
지정학적 압력 속에서 고금리에 직면한 상황에서 비즈니스 모델이 효과를 발휘할 수 있을지는 오래 기다려야 합니다. 불행히도 ACHR 주식은 조만간 성과를 거두지 못할 것으로 보이며, 이로써 캐시 우드 주식은 오늘날 매각될 또 다른 주식이 되었습니다.

https://investorplace.com/2024/05/stock-market-crash-warning-dont-get-caught-holding-these-3-cathie-wood-stocks/